
PMC:7205724 / 18627-19106
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
651 | 28-36 | Species | denotes | patients | Tax:9606 |
652 | 406-414 | Species | denotes | patients | Tax:9606 |
653 | 140-144 | Chemical | denotes | FIO2 | |
654 | 155-161 | Chemical | denotes | oxygen | MESH:D010100 |
655 | 242-260 | Chemical | denotes | methylprednisolone | MESH:D008775 |
656 | 348-366 | Chemical | denotes | methylprednisolone | MESH:D008775 |
657 | 42-50 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T141 | 104-114 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
T142 | 275-289 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
T143 | 379-393 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T138 | 42-50 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T229 | 24-27 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
T230 | 199-200 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T162 | 155-161 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T163 | 226-240 | Chemical | denotes | corticosteroid | http://purl.obolibrary.org/obo/CHEBI_50858 |
T164 | 242-260 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T165 | 348-366 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T14 | 104-134 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | lymphocyte count and decreased | http://purl.bioontology.org/ontology/MEDDRA/10025256 |
T15 | 135-150 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | PaO2/FIO2 ratio | http://purl.bioontology.org/ontology/MEDDRA/10077710 |
T16 | 155-172 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | oxygen saturation | http://purl.bioontology.org/ontology/MEDDRA/10033316 |
T17 | 275-289 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
T18 | 379-393 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T80 | 78-86 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptoms |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T103 | 155-161 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T104 | 226-240 | Chemical | denotes | corticosteroid | http://purl.obolibrary.org/obo/CHEBI_50858 |
T105 | 242-260 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T106 | 348-366 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T184 | 42-50 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T150 | 0-299 | Sentence | denotes | The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). |
T151 | 300-479 | Sentence | denotes | After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
651 | 28-36 | Species | denotes | patients | Tax:9606 |
657 | 42-50 | Disease | denotes | COVID-19 | MESH:C000657245 |
653 | 140-144 | Chemical | denotes | FIO2 | |
654 | 155-161 | Chemical | denotes | oxygen | MESH:D010100 |
655 | 242-260 | Chemical | denotes | methylprednisolone | MESH:D008775 |
656 | 348-366 | Chemical | denotes | methylprednisolone | MESH:D008775 |
652 | 406-414 | Species | denotes | patients | Tax:9606 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T18993 | 0-3 | DT | denotes | The |
T21718 | 4-9 | NN | denotes | study |
T64168 | 10-11 | -LRB- | denotes | [ |
T66430 | 11-13 | CD | denotes | 23 |
T95152 | 13-14 | -RRB- | denotes | ] |
T31198 | 15-23 | VBD | denotes | included |
T55004 | 24-27 | CD | denotes | ten |
T65830 | 28-36 | NNS | denotes | patients |
T56952 | 37-41 | IN | denotes | with |
T98815 | 42-50 | NN | denotes | COVID-19 |
T69048 | 51-54 | WP | denotes | who |
T75376 | 55-67 | VBD | denotes | demonstrated |
T59786 | 68-77 | VBG | denotes | worsening |
T24326 | 78-86 | NNS | denotes | symptoms |
T13700 | 86-87 | -COMMA- | denotes | , |
T79561 | 88-92 | FW | denotes | e.g. |
T83448 | 92-93 | -COMMA- | denotes | , |
T77014 | 94-103 | VBD | denotes | decreased |
T40148 | 104-114 | NN | denotes | lymphocyte |
T31095 | 115-120 | NN | denotes | count |
T13833 | 121-124 | CC | denotes | and |
T80531 | 125-134 | VBD | denotes | decreased |
T26060 | 135-144 | NN | denotes | PaO2/FIO2 |
T3471 | 145-150 | NN | denotes | ratio |
T11859 | 151-154 | CC | denotes | and |
T6067 | 155-161 | NN | denotes | oxygen |
T65980 | 162-172 | NN | denotes | saturation |
T58632 | 172-173 | -COMMA- | denotes | , |
T52543 | 174-183 | VBG | denotes | following |
T84435 | 184-193 | NN | denotes | treatment |
T44273 | 194-198 | IN | denotes | with |
T99668 | 199-200 | DT | denotes | a |
T65524 | 201-211 | JJ | denotes | short-term |
T66169 | 212-225 | JJ | denotes | moderate-dose |
T25963 | 226-240 | NN | denotes | corticosteroid |
T54040 | 241-242 | -LRB- | denotes | ( |
T15835 | 242-260 | NN | denotes | methylprednisolone |
T75851 | 261-268 | NN | denotes | 80 mg/d |
T55858 | 268-269 | -RRB- | denotes | ) |
T6426 | 270-274 | CC | denotes | plus |
T60445 | 275-289 | NN | denotes | immunoglobulin |
T91733 | 290-291 | -LRB- | denotes | ( |
T10263 | 291-297 | CD | denotes | 10 g/d |
T89099 | 297-298 | -RRB- | denotes | ) |
T32422 | 300-305 | IN | denotes | After |
T38661 | 306-315 | VBG | denotes | switching |
T47400 | 316-318 | TO | denotes | to |
T27854 | 319-322 | DT | denotes | the |
T88178 | 323-329 | JJ | denotes | double |
T22917 | 330-334 | NN | denotes | dose |
T27562 | 335-337 | IN | denotes | of |
T69861 | 338-347 | NN | denotes | 1600 mg/d |
T26688 | 348-366 | NN | denotes | methylprednisolone |
T91618 | 367-371 | CC | denotes | plus |
T63033 | 372-378 | NN | denotes | 20 g/d |
T82872 | 379-393 | NN | denotes | immunoglobulin |
T48110 | 393-394 | -COMMA- | denotes | , |
T64285 | 395-398 | DT | denotes | all |
T67888 | 399-401 | IN | denotes | of |
T16788 | 402-405 | DT | denotes | the |
T67776 | 406-414 | NNS | denotes | patients |
T6163 | 415-423 | VBN | denotes | improved |
T27596 | 424-426 | IN | denotes | in |
T10929 | 427-430 | DT | denotes | the |
T87507 | 431-439 | JJ | denotes | clinical |
T10805 | 439-440 | -COMMA- | denotes | , |
T49266 | 441-451 | NN | denotes | laboratory |
T95692 | 451-452 | -COMMA- | denotes | , |
T51590 | 453-456 | CC | denotes | and |
T63732 | 457-469 | JJ | denotes | paraclinical |
T58895 | 470-478 | NNS | denotes | outcomes |
R50369 | T21718 | T18993 | arg1Of | study,The |
R14407 | T21718 | T64168 | arg1Of | study,[ |
R76274 | T66430 | T64168 | arg2Of | 23,[ |
R38202 | T95152 | T64168 | arg3Of | ],[ |
R86526 | T21718 | T31198 | arg1Of | study,included |
R31769 | T65830 | T31198 | arg2Of | patients,included |
R46612 | T65830 | T55004 | arg1Of | patients,ten |
R25333 | T65830 | T56952 | arg1Of | patients,with |
R9661 | T98815 | T56952 | arg2Of | COVID-19,with |
R66734 | T98815 | T69048 | arg1Of | COVID-19,who |
R31347 | T98815 | T75376 | arg1Of | COVID-19,demonstrated |
R59919 | T24326 | T75376 | arg2Of | symptoms,demonstrated |
R40351 | T24326 | T59786 | arg1Of | symptoms,worsening |
R92905 | T31198 | T13700 | arg1Of | included,"," |
R16771 | T13833 | T13700 | arg2Of | and,"," |
R26629 | T13833 | T79561 | arg1Of | and,e.g. |
R4076 | T13833 | T83448 | arg1Of | and,"," |
R17219 | T21718 | T77014 | arg1Of | study,decreased |
R22057 | T31095 | T77014 | arg2Of | count,decreased |
R79029 | T31095 | T40148 | arg1Of | count,lymphocyte |
R1770 | T77014 | T13833 | arg1Of | decreased,and |
R37459 | T80531 | T13833 | arg2Of | decreased,and |
R47262 | T21718 | T80531 | arg1Of | study,decreased |
R34129 | T11859 | T80531 | arg2Of | and,decreased |
R19341 | T3471 | T26060 | arg1Of | ratio,PaO2/FIO2 |
R92577 | T3471 | T11859 | arg1Of | ratio,and |
R40508 | T65980 | T11859 | arg2Of | saturation,and |
R18986 | T65980 | T6067 | arg1Of | saturation,oxygen |
R39324 | T13833 | T58632 | arg1Of | and,"," |
R49635 | T13833 | T52543 | arg1Of | and,following |
R4003 | T6426 | T52543 | arg2Of | plus,following |
R22662 | T84435 | T44273 | arg1Of | treatment,with |
R78212 | T25963 | T44273 | arg2Of | corticosteroid,with |
R70976 | T25963 | T99668 | arg1Of | corticosteroid,a |
R50003 | T25963 | T65524 | arg1Of | corticosteroid,short-term |
R2970 | T25963 | T66169 | arg1Of | corticosteroid,moderate-dose |
R89182 | T25963 | T54040 | arg1Of | corticosteroid,( |
R82941 | T75851 | T54040 | arg2Of | 80 mg/d,( |
R99800 | T55858 | T54040 | arg3Of | ),( |
R95496 | T75851 | T15835 | arg1Of | 80 mg/d,methylprednisolone |
R36752 | T84435 | T6426 | arg1Of | treatment,plus |
R79540 | T60445 | T6426 | arg2Of | immunoglobulin,plus |
R41260 | T60445 | T91733 | arg1Of | immunoglobulin,( |
R75502 | T10263 | T91733 | arg2Of | 10 g/d,( |
R50386 | T89099 | T91733 | arg3Of | ),( |
R26413 | T6163 | T32422 | arg1Of | improved,After |
R62745 | T38661 | T32422 | arg2Of | switching,After |
R35046 | T64285 | T38661 | arg1Of | all,switching |
R97543 | T38661 | T47400 | arg1Of | switching,to |
R45642 | T22917 | T47400 | arg2Of | dose,to |
R79576 | T22917 | T27854 | arg1Of | dose,the |
R56085 | T22917 | T88178 | arg1Of | dose,double |
R64025 | T22917 | T27562 | arg1Of | dose,of |
R36622 | T91618 | T27562 | arg2Of | plus,of |
R47040 | T26688 | T69861 | arg1Of | methylprednisolone,1600 mg/d |
R96957 | T26688 | T91618 | arg1Of | methylprednisolone,plus |
R59825 | T82872 | T91618 | arg2Of | immunoglobulin,plus |
R2563 | T82872 | T63033 | arg1Of | immunoglobulin,20 g/d |
R17542 | T6163 | T48110 | arg1Of | improved,"," |
R33163 | T64285 | T67888 | arg1Of | all,of |
R47106 | T67776 | T67888 | arg2Of | patients,of |
R68832 | T67776 | T16788 | arg1Of | patients,the |
R41521 | T64285 | T6163 | arg1Of | all,improved |
R92060 | T6163 | T27596 | arg1Of | improved,in |
R79224 | T58895 | T27596 | arg2Of | outcomes,in |
R14909 | T58895 | T10929 | arg1Of | outcomes,the |
R43963 | T58895 | T87507 | arg1Of | outcomes,clinical |
R46705 | T87507 | T10805 | arg1Of | clinical,"," |
R31644 | T49266 | T10805 | arg2Of | laboratory,"," |
R53992 | T58895 | T49266 | arg1Of | outcomes,laboratory |
R52803 | T51590 | T95692 | arg1Of | and,"," |
R16749 | T10805 | T51590 | arg1Of | ",",and |
R63324 | T63732 | T51590 | arg2Of | paraclinical,and |
R41915 | T58895 | T63732 | arg1Of | outcomes,paraclinical |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T141 | 104-114 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
T142 | 275-289 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
T143 | 379-393 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T133 | 42-50 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T150 | 0-299 | Sentence | denotes | The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). |
T151 | 300-479 | Sentence | denotes | After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes. |